Currently several clinical trials with different antibodies targeting the PD-1/PD-L1 interaction are ongoing in combination with CTLA-4 inhibition, in combination with chemotherapy, or in combination with hypomethylating agents that upregulate the expression of PD-L1 on leukemia cells (76). This evidence concerns the gene CD274 and leukemia.